RxDoctor Payments Data

Shannon York Conrey, APRN

Family · Fort Myers, FLNPI 1649294380

Payments from drug & device makers

$938in general payments, 2019–2025

Across 32 payments — averaging $29.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$631
  • Merz North America, Inc.$109
  • Lilly USA, LLC$41
  • Currax Pharmaceuticals LLC$29
  • Merck$28
  • Amgen$25
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$938100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$938 in reported general payments places this provider in the 65th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$35,692
Medicare patients
130
Services billed
1,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$34,646
MounjaroTirzepatide17$17,193
Levothyroxine Sodium87$1,083
Omeprazole55$859
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$611
Albuterol Sulfate HfaAlbuterol Sulfate22$590
Atorvastatin Calcium72$538
Alprazolam83$378
Losartan Potassium35$375
Rosuvastatin Calcium29$363
Valsartan12$353
Amlodipine Besylate53$345
Simvastatin30$330
Bupropion XlBupropion Hcl19$330
Glimepiride19$283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$41$17,19317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 14,618 family providers in Florida.

Other family in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →